We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time

By LabMedica International staff writers
Posted on 03 Aug 2020
A Swiss-German team of researchers have developed a test that determines the amount of neutralizing antibodies against SARS-CoV-2 within a short period of time.

The test was developed at the Institute of Virology and Immunology (IVI) of the University of Bern (Bern, Switzerland) and the Swiss Federal Office for Food Safety and Animal Health (Köniz, Switzerland), and evaluated by the Ruhr-University Bochum (RUB Bochum, Germany) using serum samples from COVID-19 patients.

To determine immunity to SARS-CoV-2 and the effectiveness of potential vaccines, the amount of neutralizing antibodies in the blood of recovered or vaccinated individuals must be determined. More...
A traditional neutralization test usually takes two to three days and must be carried out with infectious coronaviruses in a laboratory complying with biosafety level 3. The new test launched by the team of Swiss-German researchers takes only 18 hours and does not have high biosafety requirements.

In order to detect antibodies against SARS-CoV-2, the researchers used another virus that does not propagate and exchanged the envelope protein of this virus for the spike protein of the novel coronavirus, which mediates virus entry and infection. As a result, the viruses can be identified by antibodies against SARS-CoV-2 that bind to the viruses which have been altered in this way and neutralize them so that they can no longer penetrate the host cells. Since the virus pseudotyped in this way cannot propagate in host cells, no elaborate biosafety precautions are necessary for the test.

In order to determine the amount of antibodies, the researchers genetically modified the virus so that green fluorescent protein and luciferase, an enzyme from fireflies, will be produced by the infected cells. The green fluorescence is an indicator of infection with the pseudotyped virus. The less green cells found, the more neutralizing antibodies are present which block the virus. In addition, a luminometer can be used to read the luminescence signal produced by the luciferase enzyme – another way of evaluating the test.

In order to check the reliability and comparability with the conventional neutralization test, the researchers applied it to blood samples from COVID-19 patients. The direct comparison showed a good correlation between the two test systems. As compared to 56 hours for the conventional test, the new test is much faster, with only 18 hours to test results.

Related Links:
University of Bern
Swiss Federal Office for Food Safety and Animal Health
Ruhr-University Bochum



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.